India Poised to Become Leading Hub for Clinical Trials Amid Global Disruptions
India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of disruptions such as the Russia-Ukraine war, an executive at contract research firm Parexel told Reuters on Wednesday. The country's growing reputation for conducting trials is driven by factors such as lower costs and a more favorable regulatory environment compared to other regions like China. India's clinical trials data market is estimated to touch $1.51 billion in 2025, according to U.S.-based GrandView Research.
- As the global pharmaceutical industry shifts its focus towards India as a trusted region for conducting trials, it raises questions about the long-term sustainability of this trend and whether other countries will follow suit.
- How can Indian authorities effectively address existing regulatory challenges to establish clinical trials as a mainstream sector in the country?